Literature DB >> 10205267

The promoters of the survival motor neuron gene (SMN) and its copy (SMNc) share common regulatory elements.

A Echaniz-Laguna1, P Miniou, D Bartholdi, J Melki.   

Abstract

Spinal muscular atrophy (SMA) is a common autosomal recessive neuromuscular disorder characterized by degeneration of motor neurons of the spinal cord. The survival motor neuron gene (SMN) has been recognized as the disease-causing gene. SMN is duplicated, and the almost identical copy gene (SMNc) remains functional in patients with SMA. The expression level of SMNc is tightly correlated with the clinical severity of the disease. Here, we define the transcription initiation site, delineate the region containing promoter activity, and analyze the sequence of the promoter region of both SMN and SMNc. We show that the promoter sequence and activity of the two genes are quasi identical, providing strong evidence for similar transcription regulation of the two genes. Therefore, the difference in the level of protein encoded by SMN and SMNc is the result of either different regulatory region(s) further apart or different posttranscriptional regulation. Interestingly, sequence analysis of the promoter region revealed several consensus binding sites for transcription factors. Therefore, the identification of transcription factors involved in the regulation of SMNc gene expression may lead to attractive strategies for therapy in SMA.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10205267      PMCID: PMC1377872          DOI: 10.1086/302372

Source DB:  PubMed          Journal:  Am J Hum Genet        ISSN: 0002-9297            Impact factor:   11.025


  21 in total

1.  Reporter constructs with low background activity utilizing the cat gene.

Authors:  M Boshart; M Klüppel; A Schmidt; G Schütz; B Luckow
Journal:  Gene       Date:  1992-01-02       Impact factor: 3.688

2.  Correlation between severity and SMN protein level in spinal muscular atrophy.

Authors:  S Lefebvre; P Burlet; Q Liu; S Bertrandy; O Clermont; A Munnich; G Dreyfuss; J Melki
Journal:  Nat Genet       Date:  1997-07       Impact factor: 38.330

3.  Distribution of simple repetitive (TG/CA)n and (CT/AG)n sequences in human and rodent genomes.

Authors:  J Tripathi; S K Brahmachari
Journal:  J Biomol Struct Dyn       Date:  1991-10

4.  CREM gene: use of alternative DNA-binding domains generates multiple antagonists of cAMP-induced transcription.

Authors:  N S Foulkes; E Borrelli; P Sassone-Corsi
Journal:  Cell       Date:  1991-02-22       Impact factor: 41.582

5.  A novel nuclear structure containing the survival of motor neurons protein.

Authors:  Q Liu; G Dreyfuss
Journal:  EMBO J       Date:  1996-07-15       Impact factor: 11.598

Review 6.  Transcription factors responsive to cAMP.

Authors:  P Sassone-Corsi
Journal:  Annu Rev Cell Dev Biol       Date:  1995       Impact factor: 13.827

7.  Human beta-interferon gene expression is regulated by an inducible enhancer element.

Authors:  S Goodbourn; K Zinn; T Maniatis
Journal:  Cell       Date:  1985-06       Impact factor: 41.582

8.  Identification and characterization of a spinal muscular atrophy-determining gene.

Authors:  S Lefebvre; L Bürglen; S Reboullet; O Clermont; P Burlet; L Viollet; B Benichou; C Cruaud; P Millasseau; M Zeviani
Journal:  Cell       Date:  1995-01-13       Impact factor: 41.582

9.  cDNA cloning of human N-Oct3, a nervous-system specific POU domain transcription factor binding to the octamer DNA motif.

Authors:  E Schreiber; A Tobler; U Malipiero; W Schaffner; A Fontana
Journal:  Nucleic Acids Res       Date:  1993-01-25       Impact factor: 16.971

10.  De novo and inherited deletions of the 5q13 region in spinal muscular atrophies.

Authors:  J Melki; S Lefebvre; L Burglen; P Burlet; O Clermont; P Millasseau; S Reboullet; B Bénichou; M Zeviani; D Le Paslier
Journal:  Science       Date:  1994-06-03       Impact factor: 47.728

View more
  28 in total

1.  The Antisense Transcript SMN-AS1 Regulates SMN Expression and Is a Novel Therapeutic Target for Spinal Muscular Atrophy.

Authors:  Constantin d'Ydewalle; Daniel M Ramos; Noah J Pyles; Shi-Yan Ng; Mariusz Gorz; Celeste M Pilato; Karen Ling; Lingling Kong; Amanda J Ward; Lee L Rubin; Frank Rigo; C Frank Bennett; Charlotte J Sumner
Journal:  Neuron       Date:  2016-12-22       Impact factor: 17.173

Review 2.  Small Molecules in Development for the Treatment of Spinal Muscular Atrophy.

Authors:  Alyssa N Calder; Elliot J Androphy; Kevin J Hodgetts
Journal:  J Med Chem       Date:  2016-08-16       Impact factor: 7.446

Review 3.  Advances in therapeutic development for spinal muscular atrophy.

Authors:  Matthew D Howell; Natalia N Singh; Ravindra N Singh
Journal:  Future Med Chem       Date:  2014-06       Impact factor: 3.808

Review 4.  Assays for the identification and prioritization of drug candidates for spinal muscular atrophy.

Authors:  Jonathan J Cherry; Dione T Kobayashi; Maureen M Lynes; Nikolai N Naryshkin; Francesco Danilo Tiziano; Phillip G Zaworski; Lee L Rubin; Jill Jarecki
Journal:  Assay Drug Dev Technol       Date:  2014-08       Impact factor: 1.738

5.  Discovery of a Small Molecule Probe That Post-Translationally Stabilizes the Survival Motor Neuron Protein for the Treatment of Spinal Muscular Atrophy.

Authors:  Anne Rietz; Hongxia Li; Kevin M Quist; Jonathan J Cherry; Christian L Lorson; Barrington G Burnett; Nicholas L Kern; Alyssa N Calder; Melanie Fritsche; Hrvoje Lusic; Patrick J Boaler; Sungwoon Choi; Xuechao Xing; Marcie A Glicksman; Gregory D Cuny; Elliot J Androphy; Kevin J Hodgetts
Journal:  J Med Chem       Date:  2017-05-19       Impact factor: 7.446

Review 6.  A survey of transcripts generated by spinal muscular atrophy genes.

Authors:  Natalia N Singh; Eric W Ottesen; Ravindra N Singh
Journal:  Biochim Biophys Acta Gene Regul Mech       Date:  2020-05-06       Impact factor: 4.490

Review 7.  Mechanism of Splicing Regulation of Spinal Muscular Atrophy Genes.

Authors:  Ravindra N Singh; Natalia N Singh
Journal:  Adv Neurobiol       Date:  2018

Review 8.  Perspectives on clinical trials in spinal muscular atrophy.

Authors:  Kathryn J Swoboda; John T Kissel; Thomas O Crawford; Mark B Bromberg; Gyula Acsadi; Guy D'Anjou; Kristin J Krosschell; Sandra P Reyna; Mary K Schroth; Charles B Scott; Louise R Simard
Journal:  J Child Neurol       Date:  2007-08       Impact factor: 1.987

9.  Refined characterization of the expression and stability of the SMN gene products.

Authors:  Jérémie Vitte; Coralie Fassier; Francesco D Tiziano; Cécile Dalard; Sabrina Soave; Natacha Roblot; Christine Brahe; Pascale Saugier-Veber; Jean Paul Bonnefont; Judith Melki
Journal:  Am J Pathol       Date:  2007-08-23       Impact factor: 4.307

10.  Effects of 2,4-diaminoquinazoline derivatives on SMN expression and phenotype in a mouse model for spinal muscular atrophy.

Authors:  Matthew E R Butchbach; Jasbir Singh; Margrét Thorsteinsdóttir; Luciano Saieva; Elzbieta Slominski; John Thurmond; Thorkell Andrésson; Jun Zhang; Jonathan D Edwards; Louise R Simard; Livio Pellizzoni; Jill Jarecki; Arthur H M Burghes; Mark E Gurney
Journal:  Hum Mol Genet       Date:  2009-11-06       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.